|Mr. Said Samih Taleb Darwazah||Exec. Chairman||3.45M||N/A||1957|
|Mr. Sigurdur Oli Olafsson Ph.D.||CEO & Exec. Director||5.42M||N/A||1969|
|Mr. Mazen Samih Taleb Darwazah||Exec. Vice Chairman & Pres of MENA||2.42M||N/A||1958|
|Mr. Khalid Walid Hussni Nabilsi||Chief Financial Officer||N/A||N/A||1972|
|Dr. Surendera Tyagi||Group Chief Scientific Officer and Global Head of R&D||N/A||N/A||N/A|
Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment manufactures, markets, and sells generic injectable products for therapeutic categories, including oncology and anti-viral products to hospitals. The Generics segment develops and sells oral and other non-injectable generic products for retail market. The Branded segment develops, manufactures, and markets branded generics and in-licensed products to retail and hospital markets. The company offers products in various therapeutic areas, including respiratory, oncology, pain management, anti-infectives, cardiovascular, diabetes, and central nervous system. It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally. The company was founded in 1978 and is based in London, the United Kingdom.
Hikma Pharmaceuticals PLC’s ISS Governance QualityScore as of April 1, 2019 is 9. The pillar scores are Audit: 1; Board: 7; Shareholder Rights: 1; Compensation: 10.